Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products Seattle, WA – May 26, 2026 – Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive…Read More
Profitvelocity was a four-year old startup at the time John Supan, our partner from FLG, started working with us. We had no proper accounting systems in place. John helped us put in place, step by step, an accounting infrastructure that would allow us to grow and satisfy the requirements of our financial partners. I believe that the most vital aspects in working with a CFO, like John, are absolute trust in his integrity along with total respect for his technical knowledge in sophisticated accounting matters. Beyond that, John is remarkably responsive, often within a few hours, regardless of his workload. And he is always upbeat, easy-going, and effective even when a challenging issue pops up. I wouldn’t hesitate to hire FLG (and John) again. Collaborating with John in building up our company has been a privilege.
Michael Rothschild, Founder & CEO, Profitvelocity Read More
